It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Mixed lineage kinase domain-like (MLKL) is the terminal protein in the pro-inflammatory necroptotic cell death program. RIPK3-mediated phosphorylation is thought to initiate MLKL oligomerization, membrane translocation and membrane disruption, although the precise choreography of events is incompletely understood. Here, we use single-cell imaging approaches to map the chronology of endogenous human MLKL activation during necroptosis. During the effector phase of necroptosis, we observe that phosphorylated MLKL assembles into higher order species on presumed cytoplasmic necrosomes. Subsequently, MLKL co-traffics with tight junction proteins to the cell periphery via Golgi-microtubule-actin-dependent mechanisms. MLKL and tight junction proteins then steadily co-accumulate at the plasma membrane as heterogeneous micron-sized hotspots. Our studies identify MLKL trafficking and plasma membrane accumulation as crucial necroptosis checkpoints. Furthermore, the accumulation of phosphorylated MLKL at intercellular junctions accelerates necroptosis between neighbouring cells, which may be relevant to inflammatory bowel disease and other necroptosis-mediated enteropathies.
Mixed lineage kinase domain-like (MLKL) is the terminal protein in the pro-inflammatory necroptotic cell death program. Here the authors show that MLKL trafficking and plasma membrane accumulation are crucial necroptosis checkpoints, and that accumulation of phosphorylated MLKL at intercellular junctions promotes necroptosis.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Zhang, Ying 1 ; Geoghegan, Niall D 1 ; Gavin, Xavier J 2 ; Davies, Katherine A 1
; Mlodzianoski, Michael J 1
; Whitehead, Lachlan W 1
; Frank, Daniel 1 ; Garnish, Sarah E 1 ; Fitzgibbon Cheree 2 ; Hempel, Anne 2 ; Young, Samuel N 2 ; Jacobsen, Annette V 1
; Cawthorne, Wayne 1 ; Petrie, Emma J 1 ; Faux, Maree C 1 ; Shield-Artin Kristy 1 ; Lalaoui Najoua 1
; Hildebrand, Joanne M 1
; Silke, John 1
; Rogers, Kelly L 1 ; Lessene Guillaume 3
; Hawkins, Edwin D 1
; Murphy, James M 1
1 The Walter and Eliza Hall Institute of Medical Research, Parkville, Australia (GRID:grid.1042.7); The University of Melbourne, Department of Medical Biology, Parkville, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X)
2 The Walter and Eliza Hall Institute of Medical Research, Parkville, Australia (GRID:grid.1042.7)
3 The Walter and Eliza Hall Institute of Medical Research, Parkville, Australia (GRID:grid.1042.7); The University of Melbourne, Department of Medical Biology, Parkville, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X); The University of Melbourne, Department of Pharmacology and Therapeutics, Parkville, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X)




